Skip to main content

Vertex Value Stock - Dividend - Research Selection

Vertex Pharmaceuticals

ISIN: US92532F1003, WKN: 882807

Market price date: 03.04.2020
Market price: 238,31 USD




Vertex Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 19-02-2020
Cash flow
Net operating cash flow 1.569.330.000
Capital Expenditures -75.451.000
Free cash flow 1.493.879.040
Balance sheet
Total Equity 6.085.240.000
Liabilities & Shareholders equity 8.318.470.000
Income statement
Net income 1.176.810.000
Eps (diluted) 4,510
Diluted shares outstanding 260.933.000
Net sales/revenue 4.162.820.000

Fundamental ratios calculated on: 03-04-2020

Ratios
Key figures 03-04-2020
Cash flow
P/C 39,62
   
P/FC 41,63
Balance sheet
ROI14,15
ROE73,15
Income statement
P/E52,84
Div. Yield0,00%
P/B10,22
P/S14,94


Do you want to do make a detailed fundamental analysis of this stock?

Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolVRTX
Market Capitalization62.182.944.768,00 USD
CountryUnited States
IndicesNASDAQ 100,S&P 500
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split2000-08-24,2.0000/1.0000
Internetwww.vrtx.com


Description of the company

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.vrtx.com